

09/743682

500 F-1d PCT/PTO 10 JAN 2001

Practitioner Docket No. 586.02-US1

Pre-Grant
3A
D7
S-2-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231

Inventor: **Fahri Saatcioglu**

Serial No: U.S. National Phase
Application of PCT/IB00/00673

Filed: **May 19, 2000**

For: **Differentially Expressed
Genes in Prostate Cancer**

Examiner: Not Yet Assigned

Art Unit: Not Yet Assigned

PRELIMINARY AMENDMENT

The Honorable Commissioner
of Patents and Trademarks
Washington, D.C. 20231

Dear Sir:

Please enter the following preliminary amendment:

IN THE CLAIMS

5. (Amended) The polynucleotide of [any one of] claim 1[, 3, or 4] wherein the polynucleotide is expressed *in vivo* in a prostate cancer cell.

6. (Amended) The polynucleotide of [any one of] claim 1[, 3, or 4] wherein the expression of the polynucleotide is dependent on at least one of an androgen, a progesterone, an estrogen, and a glucocorticoid.

33. (Added) The polynucleotide of claim 3 wherein the polynucleotide is expressed *in vivo* in a prostate cancer cell.

34. (Added) The polynucleotide of claim 4 wherein the polynucleotide is expressed *in vivo* in a prostate cancer cell.

*Sub
B4*

DS